Profil
Brett T.
Staahl was the founder of Scribe Therapeutics, Inc. and held the title of Vice President-Platform.
Postes actifs de Brett T. Staahl
| Sociétés | Poste | Début |
|---|---|---|
Scribe Therapeutics, Inc.
 Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Health Technology |
